PolyTherics and Minapharm Pharmaceuticals Sign Collaboration Agreement to Create Enhanced Biopharmaceuticals
PolyTherics Limited announced the initiation of a research collaboration agreement with Minapharm Pharmaceuticals. PolyTherics will apply its proprietary drug modification technologies to a target protein of commercial interest to Minapharm. Minapharm has an option to license the collaboration intellectual property for the development and commercialisation of novel products. Minapharm also receives an option to submit further target proteins of interest to future collaborations with PolyTherics.
PolyTherics receives an upfront licence fee and further payments on achievement of defined programme milestones. Details of the agreement terms were not disclosed.
Dr Keith Powell, Chief Executive Officer of PolyTherics, said: “Through multiple partnerships, we are uncovering the considerable development potential of our PEGylation technologies to create biotherapeutic product candidates. We are looking forward to collaborating with a company with such a solid reputation in innovative pharmaceuticals development as Minapharm.”
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.